

Editorial

New GRAPPA and EULAR recommendations for the management of psoriatic arthritis

Process and challenges faced

In 2015, both the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and the EULAR presented updated recommendations on the management of PsA [1, 2]. New therapies, assessments and increasing evidence on comorbidities required substantial revision of treatment strategies.

This editorial provides comments on the key barriers faced and how these were addressed. The challenges focus around the remit of the recommendations, the scope of the literature review and assessment of the available data (Table 1).

A difference in approach is clear from the mission of the organizations. GRAPPA is a global research group dedicated to both psoriasis and PsA. Obviously, EULAR concentrates on rheumatic diseases with a European focus although recommendations are designed to be applicable internationally [3]. GRAPPA assessed both dermatological and musculoskeletal manifestations, with dermatologists leading groups focused on skin and nail disease. The EULAR recommendations focused specifically on musculoskeletal PsA, with referral to a dermatologist recommended for patients with significant skin disease but no management recommendations for skin or nail manifestations.

To address heterogeneity, both groups assessed efficacy of therapies for different domains of disease. GRAPPA presented the full data in six distinct algorithms according to predominant phenotype, allowing physicians to pick an optimal therapy based on disease activity in each domain. Given their remit, the GRAPPA recommendations include therapies for skin and nail disease in addition to musculoskeletal involvement. EULAR developed a single algorithm focused on peripheral arthritis with different pathways for enthesitis and axial disease.

To address the frequent comorbidities of PsA, the GRAPPA recommendations included recommendations based on a specific systematic literature review (SLR), including both extra-articular SpA manifestations and distinct comorbidities such as cardiovascular disease, metabolic syndrome, depression and skin cancer [4]. EULAR placed comorbidities to the forefront in the overarching principles but without an SLR or any specific recommendations.

Both organizations involved patient representatives to ensure better representation of patients' needs and uncertainties, and prevent a mismatch between their preferences and the scientific focus in research [5, 6]. Proper representation is key because the personal experience of

a patient will likely strongly influence their view. Patients in both organizations, with specific training/support, participated in development of overarching principles and recommendations discussing the evidence presented. The development of lay summaries drafted specifically for patients is currently underway.

Drafting of the GRAPPA recommendations was guided by a steering committee but appraisal of the evidence and generation of treatment recommendations was completed in specific domain subcommittees with regular feedback to the GRAPPA membership. Drafts were disseminated to members, including patient research partners to allow feedback before 145 participants voted on agreement.

The EULAR steering group defined the SLR scope. Following this, the findings of the SLR were discussed within a Taskforce, consisting of 34 people: 28 rheumatologists, 3 people affected with PsA, 2 health professionals and 1 dermatologist. There were some subsequent small modifications prior to voting on agreement by Taskforce members.

Both sets of recommendations were based on large SLRs to provide the evidence base including randomized controlled trials and data from conference abstracts. This decision to include abstracts was controversial but it was taken to ensure that the recommendations were not outdated rapidly. New therapies with data predominantly in abstract form only were included in both recommendations. These were clearly demarcated as conditional in the GRAPPA recommendations, but no order was suggested within the biologics allowing flexibility depending on the details of the case. EULAR considered all data, regardless of full-text publication status. These new therapies were included but were suggested as second line biologics as they had less accumulated experience and safety data.

The EULAR recommendations used the Oxford Centre for Evidence Based Medicine levels of evidence from 1a to 4 [7]. In contrast, GRAPPA adapted the newer Grading of Recommendations Assessment, Development and Evaluation in the latest update [8]. Grading of Recommendations Assessment, Development and Evaluation gives recommendations following assessment of desirable and undesirable consequences, quality of evidence, values and preferences, and resource use, and is now recommended by the WHO. It does present complexities, particularly given that the patient, intervention, comparator and outcome questions should be written in binary form. Given the various domains of PsA, and the

TABLE 1 Challenges for management recommendations in PsA

Scope, remit and presentation	Heterogeneity of PsA	In a heterogeneous condition such as PsA with multiple domains, should recommendations address these aspects of disease individually or attempt to create a single management strategy?
	Stakeholder involvement	Who should be involved in the development process? How should patients be involved?
Scope of the systematic literature review	Updating/perennity	In a fast moving research field, how frequently must recommendations be updated?
	Abstract data interpretation	How should data from abstracts be included, recognizing that these have not been subject to a peer review process?
Assessing the evidence	Assessment of evidence quality	What system for evidence review should be used given the complexity of the condition and limited quality of evidence in some areas?
	Lack of evidence	Is extrapolation from related conditions reasonable in certain domains of PsA, particularly axial PsA where very limited data exist?
	Conflicting evidence	How should conflicting data be balanced?
	Heterogeneity in outcome measures used	How can therapies be compared if different outcome measures are used in different trials?

growing multiplicity of treatments, creating pairwise situations creates myriad scenarios.

In some cases, PsA-specific trial data were missing and both groups relied on secondary study outcomes and extrapolated data from related conditions. The most obvious example is axial PsA where very few studies are available and evidence from axial spondyloarthritis was used.

Where good quality data are lacking, such as MTX, observational data report widespread use of MTX in PsA with reasonable response, in contrast to the negative findings in the MIPA RCT [9] that had methodological flaws [10]. In the GRAPPA recommendations, MTX is included as one of the potential DMARDs (alongside SSZ and LEF), but given the lack of conclusive evidence these were not ranked. In the EULAR recommendations, MTX is clearly listed as the first line DMARD therapy despite this controversial evidence base, due to positive expert experience and the limitations of the studies. It is difficult to synthesize the evidence from different studies because of the heterogeneity in outcome measures (e.g. enthesitis or dactylitis).

Based on the experience of both groups, the challenges to optimal development of future PsA recommendations are evident. Both groups involved rheumatologists, patient research partners and at least one dermatologist to provide a multidimensional approach. Both groups based their recommendations on a SLR and included recent data from abstracts to remain current. The groups used different methods to analyse the evidence and achieved consensus using contrasting methods, resulting in unique management algorithms with significant overlap.

Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.

Disclosure statement: L.C.C. has received honoraria and/

or grant support from Abbvie, Amgen, BMS, Boehringer Ingelheim, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer and UCB. L.G. has received grant support and honoraria from and/or has consulted for Abbvie, BMS, Celgene, Chugai, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB. A.K. has held consultancies and received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis and UCB. D.vdH. has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi, Eli Lilly, Galapagos, Gilead, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi and UCB, and is Director of Imaging Rheumatology bv. C.R. has received research support from Amgen, Abbvie and UCB and has served as a consultant for Amgen, Abbvie, Janssen, Novartis, Sun Pharma, Pfizer and UCB. P.M. has received research grants, speaker fees and consultancy honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer and UCB, research grants and consultancy honoraria from Lilly and Sun, consultancy honoraria and speaker fees from Crescendo, consultancy honoraria from Corrona, Dermira, Merck and Zynerva and speaker fees from Genetech. J.S.S. reports grants and personal fees from AbbVie, Lilly, MSD, Pfizer and Roche, personal fees from Amgen, Astra, Astro, Celgene, Chugai, GSK, ILTOO, Janssen, Novartis, Samsung, Sanofi and UCB, all outside the submitted work. The other author has declared no conflicts of interest.

Laura C. Coates^{1,*}, Laure Gossec^{2,*}, Sofia Ramiro³, Philip Mease⁴, Désirée van der Heijde³, Josef S. Smolen^{5,6}, Christopher Ritchlin^{7,*} and Arthur Kavanaugh^{8,*}

¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds UK, ²Department of rheumatology, Sorbonne Universités, UPMC Univ Paris 06; AP-HP, Pitié Salpêtrière Hospital, Paris,

France, ³Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands, ⁴Swedish Medical Center Seattle, WA, USA, ⁵Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, ⁶2nd Department of Medicine, Hietzing Hospital, Vienna, Austria, ⁷Allergy, Immunology & Rheumatology Division, University of Rochester Medical Center, Rochester, NY and ⁸Division of Rheumatology, Allergy Immunology, University of California San Diego, USA

Correspondence to: Laura Coates, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, LS7 4SA, UK. E-mail: l.c.coates@leeds.ac.uk
Revised version accepted 26 September 2016

*Laura C. Coates, Laure Gossec, Christopher Ritchlin and Arthur Kavanaugh contributed equally to this study.

References

- 1 Coates LC, Kavanaugh A, Mease PJ *et al.* Group for Research and Assessment of Psoriasis and Psoriatic Arthritis: Treatment Recommendations for Psoriatic Arthritis 2015. *Arthritis Rheumatol* 2016;68:1060–71.
- 2 Gossec L, Smolen JS, Ramiro S *et al.* European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. *Ann Rheum Dis* 2016;75:499–510.
- 3 van der Heijde D, Aletaha D, Carmona L *et al.* 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. *Ann Rheum Dis* 2015;74:8–13.
- 4 Ogdie A, Schwartzman S, Eder L *et al.* Comprehensive treatment of psoriatic arthritis: managing comorbidities and extraarticular manifestations. *J Rheumatol* 2014;41:2315–22.
- 5 de Wit MP, Berlo SE, Aanerud GJ *et al.* European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. *Ann Rheum Dis* 2011;70:722–6.
- 6 Cheung PP, de Wit M, Bingham CO 3rd *et al.* Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. *J Rheumatol* 2016;43:187–93.
- 7 OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence. Oxford: Oxford Centre for Evidence-Based Medicine. <http://www.cebm.net/ocebmllevels-of-evidence/> (20 October 2016, date last accessed).
- 8 Grading of Recommendations Assessment, Development and Evaluation. Hamilton, Ontario: McMaster University, 2014. <http://gradeworkinggroup.org/> (20 October 2016, date last accessed).
- 9 Kingsley GH, Kowalczyk A, Taylor H *et al.* A randomized placebo-controlled trial of MTX in PsA. *Rheumatology* 2012;51:1368–77.
- 10 Pincus T, Bergman MJ, Yazici Y. Limitations of clinical trials in chronic diseases: is the efficacy of methotrexate (MTX) underestimated in polyarticular psoriatic arthritis on the basis of limitations of clinical trials more than on limitations of MTX, as was seen in rheumatoid arthritis? *Clin Exp Rheumatol* 2015;33(Suppl 93):S82–93.